Hemorrhoid

Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Wednesday, September 7, 2022
BLA, Hemorrhoid, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PTCL, Food, CTCL, Multimedia, IL-2R, Fast Track, Immunotherapy, Company, FDA, Pivotal, Lotte New York Palace Hotel, T-cell lymphoma, Peripheral T-cell lymphoma, Citius, Altius, Fortius, Patient, Pharmaceutical industry

CRANFORD, N.J., Sept. 7, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), today announced that Citius will participate in the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022. Leonard Mazur, Chairman and CEO of Citius, will present in person on September 14, 2022 at 11:00am EDT, and host one-on-one meetings with investors.

Key Points: 
  • Mino-Lokwas granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
  • I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL).
  • In the first half of 2022, Citius initiated a Phase 2b trial for Halo-Lido, a topical formulation for the relief of hemorrhoids.
  • The Company anticipates completing enrollment in the Halo-Lido trial by the end of 2022.

Hemorrhoids Epidemiology Forecasts Report 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 27, 2022
Pharmaceutical, Health, Other Health, SME, Diagnosis, United Kingdom, Disease, Epidemiology, Classification, Table, Lists of people executed in the United States, Vaccine, Dentistry, Renewable energy, Hemorrhoid

This "Hemorrhoids - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Hemorrhoids epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This "Hemorrhoids - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Hemorrhoids epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Hemorrhoids epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries.
  • The Hemorrhoids epidemiology covered in the report provides historical as well as forecasted Hemorrhoids epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
  • The Hemorrhoids report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
    The Hemorrhoids Epidemiology Report and Model provide an overview of the global trends of Hemorrhoids in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
    The report provides insight into the historical and forecasted patient pool of Hemorrhoids in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan

Worldwide Compound Camphor Ointment Industry to 2027 - Increasing Incidence of Fungal Infections and Inflammatory Conditions is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, May 27, 2022
Health, General Health, Joint, Pain, Population, Ageing, Swelling, World, Pachydactylus labialis, Patient, Woman, World Health Organization, Joint Medical Service (Germany), Pain management, Government, OTC, Osteoarthritis, Muscle, Obesity, Administration, Arthritis, Bruise, Efficiency, Awareness, Probability, WHO, Accident, Hemorrhoid, Disability, Man, Analgesic, Adoption, Headache, Injury, CAGR, Itch, Wart, Prevalence, Growth, Pharmacy, Lists of countries and territories, Dietary supplement, Health insurance

In addition, a huge population inclined toward a sedentary lifestyle and obesity is also expected to drive the growth of the market.

Key Points: 
  • In addition, a huge population inclined toward a sedentary lifestyle and obesity is also expected to drive the growth of the market.
  • This trend is expected to continue positively, influencing the demand for compound camphor ointment.
  • The demand for OTC-related compound camphor ointment is expected to increase during the forecast period, due to the easy availability of these products in retail pharmacies.
  • Increasing product adoption & cognizance and incremental rise in the number of patients has also been accelerating market growth in the region.

Global Gastrointestinal Drugs Market Report 2022: Focus on Antacids, Antiulcerants, Antiobesity, Antiemetics and Antinauseants, & Antidiarrhoeals - Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 17, 2022
Health, Pharmaceutical, Proton, Joint Medical Service (Germany), Reckitt, Constipation, Irritable bowel syndrome, Population, Ageing, Antiemetic, Daiichi Sankyo, Ulcerative colitis, Rockies Express Pipeline, Degenerative disease, Sucralfate, Proton-pump inhibitor, Antibody, Diverticular disease, Bayer, Route of administration, COVID-19, Prescription drug purchasing pool, Patent, Johnson & Johnson, Inflammatory bowel disease, Peptide, Procter & Gamble, WHO, Anal fissure, Hemorrhoid, Antacid, Heartburn, Organization, Eli Lilly, Takeda Pharmaceutical Company, Proton pump, Protein, Antidiarrhoeal, CAGR, Growth, Abbott Laboratories, Gastrointestinal tract, Fine chemical, Dietary supplement, Pharmaceutical industry, Misoprostol

The global gastrointestinal drugs market is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%.

Key Points: 
  • The global gastrointestinal drugs market is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%.
  • The gastrointestinal drugs market consists of sales of gastrointestinal drugs by entities (organizations, sole traders and partnerships) that produce gastrointestinal drugs to treat gastrointestinal diseases such as ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome.
  • The main types of gastrointestinal drugs are antacids, antiulcerants, antiobesity, antiemetics and antinauseants and antidiarrhoeals.
  • During the forecast period, the growth of the gastrointestinal drugs market will be restrained by patent expiration of branded gastrointestinal drugs.

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 12, 2022
COVID-19, U.S. Securities and Exchange Commission, Risk, Company, Consultant, Immunotherapy, G&A, Regulation of tobacco by the U.S. Food and Drug Administration, Infection, Food, Pivotal, Peripheral T-cell lymphoma, T-cell lymphoma, Potency (pharmacology), Patient, Insurance, Quality of life, CGMP, BLA, PTCL, Research, Patent, FDA, Securities Act of 1933, Accounting, Securities Exchange Act of 1934, Hemorrhoid, CRO, Forward-looking statement, IL-2R, Drug Quality and Security Act, Calendar, Regulation, Fast Track, SEC, Annual report, CTCL, CEO, Pharmaceutical industry, Security (finance), Fine chemical, Online gambling, Airline, Citius, Altius, Fortius, Novellus Systems

CRANFORD, N.J., May 12, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today reported business and financial results for the second fiscal quarter of 2022 ended March 31, 2022.

Key Points: 
  • "The Citius balance sheet remains healthy with $55.8 million in cash available to execute our near-term plans.
  • As stewards of Citius shareholders' capital, we focus on creating long-term value in the business and will continue to evaluate all strategic and financial options available to us.
  • SECOND QUARTER ENDED MARCH 31, 2022 Financial Results:
    As of March 31, 2022, the Company had $55.8 million in cash and cash equivalents and no debt.
  • For the fiscal quarter ended March 31, 2022, stock-based compensation expense was $1.0 million as compared to $0.3 million for the prior year period.

Citius Pharmaceuticals, Inc. Provides Business Update, Highlights Upcoming Milestones

Retrieved on: 
Tuesday, May 3, 2022
COVID-19, CTCL, Forward-looking statement, DMC, T-cell lymphoma, Company, Hemorrhoid, EPRO, Securities Act of 1933, PTCL, Food, Securities Exchange Act of 1934, CGMP, Peripheral T-cell lymphoma, Patient, Immunotherapy, COVID, BLA, IL-2R, Program, FDA, Annual report, Drug Quality and Security Act, Patent, Regulation of tobacco by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Multimedia, Potency (pharmacology), Fast Track, Quality of life, Pivotal, SEC, CEO, Regulation, Research, Fine chemical, Pharmaceutical industry, Citius, Altius, Fortius

CRANFORD, N.J., May 3, 2022 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products,today provided a business update for the first quarter ended March 31, 2022 and reported on recent corporate developments and upcoming milestones.

Key Points: 
  • CRANFORD, N.J., May 3, 2022 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products,today provided a business update for the first quarter ended March 31, 2022 and reported on recent corporate developments and upcoming milestones.
  • "2022 is a year of important catalysts for Citius as we continue to make progress on multiple fronts.
  • We recently released topline results for I/ONTAK which were consistent with the prior FDA-approved and marketed formulation of denileukin diftitox (ONTAK).
  • Citius considers all strategic alternatives to maximize the value of our portfolio, individually and collectively, on an ongoing basis.

Citius Pharmaceuticals Enrolls First Patient in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Retrieved on: 
Tuesday, April 26, 2022
COVID-19, Tenderness, Patent, Ulobetasol, Potency (pharmacology), Patient, EPRO, Pain, Clinical trial, T-cell lymphoma, Population, Pivotal, Goligher, Regulation of tobacco by the U.S. Food and Drug Administration, Research, U.S. Securities and Exchange Commission, Peripheral T-cell lymphoma, Degenerative disease, Life, Immunotherapy, Bleeding, Food, Regulation, Annual report, Drug Quality and Security Act, Securities Exchange Act of 1934, Hemorrhoid, Trial of the century, Lidocaine, Company, Itch, SEC, CGMP, Forward-looking statement, PTCL, Safety, IL-2R, Fast Track, Multimedia, FDA, Quality of life, Securities Act of 1933, CTCL, Swelling, Pharmaceutical industry, Citius, Altius, Fortius

CRANFORD, N.J., April 26, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the first patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido for the treatment of hemorrhoids.  If approved, Halo-Lido would be the first FDA-approved prescription product indicated for the treatment of hemorrhoids.

Key Points: 
  • If approved, Halo-Lido would be the first FDA-approved prescription product indicated for the treatment of hemorrhoids.
  • The Phase 2b study is a multi-center, randomized, dose-ranging, double-blind, parallel group comparison clinical trial.
  • Five cohorts of adults with a clinical diagnosis of symptomatic Goligher's classification Grade II or Grade III hemorrhoids will be dosed.
  • The study will evaluate reduction in hemorrhoidal symptoms (including: pain, burning, itching, and swelling) following treatment and is expected to provide the foundation for development of the Phase 3 study.

Solera Health Launches Digestive Health Offering with Best-in-Class Digital Therapy Solutions: Oshi Health and Vivante Health

Retrieved on: 
Monday, March 28, 2022
Degenerative disease, Cancer, Life, Health, Diverticular disease, Functional constipation, Mental health, IBS, Diagnosis, ER, Autoimmunity, Common, GERD, Program, Gastroesophageal reflux disease, CEO, Prevalence, GI, Quality of life, Irritable bowel syndrome, Industry, Hemorrhoid, Mental, Inflammatory bowel disease, Disorder, Esophageal motility disorder, Human musculoskeletal system, Solution, Intracellular digestion, Patient, Partnership, Health insurance, Oshi, PHOENIX, Solera

PHOENIX , March 28, 2022 /PRNewswire/ -- Solera Health, the premier platform for connecting people seamlessly and easily to health solutions that work, announces the launch of its new Digestive Health offering with leading digital therapy solutions: Oshi Health and Vivante Health. These new network partners continue Solera's strategy of bringing programs that address the diverse clinical needs of their payer and employer member populations. All network partners were carefully selected after an extensive vetting process to ensure that they met Solera's high standards for efficacy and customer satisfaction. With Solera's unique value-based payment model, payers and employers get high-quality solutions focused on engagement and industry benchmarked outcomes.

Key Points: 
  • "Digestive Health diseases affect nearly one in five Americans and cost more than $140B per year in direct and indirect costs to employers and health plans," said Mary Langowski, CEO, Solera Health.
  • Oshi Health has redesigned digestive health care around what patients really need and want: convenient, supportive care that quickly achieves sustainable symptom control.
  • Our all-in-one digestive health program, GIThrive, empowers peoplethrough innovative technology, advanced science, and on-demand human supportto improve digestive health, while lowering their cost of care.
  • Vivante Health provides positive patient outcomes at scale for large employers, including multiple fortune 500 companies and leading health plans.

Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Retrieved on: 
Tuesday, February 15, 2022
Potency (pharmacology), Itch, Patient, EPRO, CTCL, Food, Hemorrhoid, Quality of life, Company, Goligher, SEC, Immunotherapy, T-cell lymphoma, Smartphone, Regulation, Degenerative disease, Pressure, Drug Quality and Security Act, Lidocaine, Annual report, Safety, Securities Exchange Act of 1934, IL-2R, Regulation of tobacco by the U.S. Food and Drug Administration, Forward-looking statement, Pain, Pivotal, Securities Act of 1933, U.S. Securities and Exchange Commission, PTCL, CGMP, FDA, Bleeding, Population, Tenderness, Ulobetasol, Patent, Peripheral T-cell lymphoma, Research, Multimedia, COVID-19, Fast Track, Life, Swelling, Pharmaceutical industry, Citius, Altius, Fortius

The Company is addressing recommendations made by the FDA and anticipates initiating a Phase 2b clinical study in the first half of 2022.

Key Points: 
  • The Company is addressing recommendations made by the FDA and anticipates initiating a Phase 2b clinical study in the first half of 2022.
  • Halo-Lido is a proprietary topical formulation of halobetasol and lidocaine that is intended to provide symptomatic relief to individuals suffering from hemorrhoids.
  • We have worked closely with the FDA to design our Phase 2b study protocol and look forward to beginning the study in the coming months," stated Myron Holubiak, Chief Executive Officer of Citius.
  • The Phase 2b study is designed as a multi-center, randomized, dose-ranging, double-blind, parallel group comparison.

New York Bariatric Group Establishes NYBG Colorectal Flagship in New Jersey

Retrieved on: 
Tuesday, February 8, 2022
Empathy, NYBG, Solution, Large intestine, Colorectal cancer, Ulcerative colitis, Fissure, Patient, Quality of life, Crohn's disease, Hemorrhoid, Dentistry

ROSLYN HEIGHTS, N.Y., Feb. 8, 2022 /PRNewswire/ -- New York Bariatric Group (NYBG), the advanced weight loss surgery center with the country's most accomplished bariatric surgeons establishes NYBG Colorectal in Glen Ridge, New Jersey.

Key Points: 
  • ROSLYN HEIGHTS, N.Y., Feb. 8, 2022 /PRNewswire/ -- New York Bariatric Group (NYBG), the advanced weight loss surgery center with the country's most accomplished bariatric surgeons establishes NYBG Colorectal in Glen Ridge, New Jersey.
  • Harnessing NYBG surgical excellence, NYBG Colorectal was designed to provide cutting-edge treatment for the most sensitive and painful colorectal issues.
  • NYBG Colorectal is an affiliate of the New York Bariatric Group, the recognized leader in bariatric surgical procedures raises the standard of treatment with the most recently developed, innovative technologies and surgical techniques.
  • NYBG Colorectal is committed to finding solutions for sensitive and painful colorectal issues such as hemorrhoids, fissures, and diseases such as Crohn's, pilonidal, ulcerative colitis, and colorectal cancer.